drugset / Trial / NCT05145608

Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg

NCT05145608

Phase 1 Completed 22 enrolled Alembic Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

Objective: To evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of lamotrigine after a single oral dose administration under fasting conditions. The secondary objective is to monitor the safety of the subjects.

Timeline

Start
2018-01-10
Primary completion
2018-02-21
Completion
2018-02-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lamotrigine Small molecule 50 mg Oral

Indications

No indication recorded.